Nutra Pharma Corp (NPHC)

[fly_fisherman]

Big Pharma needs NPHC...


NPHC Massively undervalued has the potential to become a small cap stock. While pharma is getting hit over opioid's, Nutra Pharm with an opioid alternative could become a buyout candidate. Not many opioid alternative pain solutions out there. The time to bring a new alternative solution to market can take years. Nyloxin outperforms morphine!


Over prescribing, Insurers and pharmacy benefit managers must better oversee opioid prescriptions, State and local governments can do more to name a few in the article.

Finally over prescribing is being addressed, insurers and pharmacy's are beginning to place limitations on opiates. This being the case I have posted articles where a huge concern with the limitations to opiates creates problems in cases where folks need on going pain relief treatment.

Just stopping opiates is NOT a solution. A growing need exists for alternatives that can vary in strength but also has no side effects and is non addictive.

Nyloxin is all-natural, anti-inflammatory, analgesic pain relief that is non-toxic, non-narcotic, non-addictive, non-steroidal and does not contain aspirin or acetaminophen !!!

“Nyloxin product is amazing. It’s non-addictive, no opiate, non-narcotic. In the last model, it outperformed morphine. It lasted 4-6 hours longer than morphine without any of the side effects. Additionally, since the dose of Nyloxin is so small compared to the dose of morphine required, the Nyloxin was considered to be approximately 600 times more potent than the morphine on a molecular basis.,” explained Rik Deitsch, CEO of Nutra Pharma Corp.

By limiting the prescriptions and insurers doing their part to limit opiates this takes away a revenue stream to big pharma. Not only are they having revenues reduced they are also facing law suites and huge settlements. Pharma's are losing revenues and getting their pocket books hit with settlements. Pharma NEEDS what NPHC has to offer!!

To re-iterate the crisis needs an alternative not only to the folks suffering but also for the big pharma. There is no doubt Nyloxin, which can be modified to various strengths, can be an alternative. This will entail either licensing or possibly a buyout.

Its coming, the pieces are all coming together for Rik and Nutra Pharma. I personally like investing in a company that is providing a helpful solution to such devastating crisis.

Nice to see a company that keeps the same business description over 2 years. Heck NPCH has been the same for over 10 years. Typical OTC is to switch business descriptions every two years to rinse and repeat and create no value. Nutra Pharma is not a flash in the pan MJ or Bitcoin stock. Nutra Pharma is here to stay and GROW!

Business Description
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin and Pet Pain-Away.


Also nice to see Nutra Pharma Corp. (NPHC) is Current, fully SEC reporting with audited financials. A few months back a QB stock. Will be back there soon! Folks, most pinks are not even current and are alternative reporting standard and unaudited.


Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials: Audited
Latest Report: Sep 30, 2017 10-Q
CIK: 0001119643
Fiscal Year End: 12/31
OTC Marketplace: Pink Current


https://www.otcmarkets.com/stock/NPHC/profile

$$NPHC$$ Short term target .01 to .05 ... with "Orphan Drug Status for pediatric MS" EVEN HIGHER!


SUPPORTING ARTICLES:


AG Matt Denn takes on Big Pharma in opioid lawsuit

January 19, 2018

https://www.delawareonline.com/story/news/local/heroindelaware/2018/01/19/ag-matt-denn-takes-big-pharma-opioid-lawsuit/1046672001/

How to end the opioid crisis in seven steps

January 15, 2018

https://www.jsonline.com/story/opinion/2018/01/15/end-opioid-crisis-seven-steps/109477518/



Chronic Pain Sufferers Say They're Paying the Price for Opioid Epidemic

January 2, 2018


http://www.dallasobserver.com/news/chronic-pain-sufferers-say-theyre-paying-the-price-for-opioid-epidemic-10211176

===

Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More

The alternative pipeline you will note in the article below is THIN

November 3, 2017

https://www.xconomy.com/national/2017/11/03/biotech-roundup-opioid-news-ash-preview-boston-bio-ipos-more/

The rising death toll from opioids has prompted policymakers to try various ways to take on the problem. President Trump’s opioid commission released its final report this week, calling for expansion of drug courts, better physician training, and penalties for insurers that don’t cover treatment.

But the commission did not say how much its recommendations would cost, nor did it offer a way to pay for them. The absence of those details highlight the difficulties in addressing the crisis. One option is offering other, non-addictive medications. But as an Xconomy report noted, the pipeline of alternatives is thin due to various challenges developing new pain drugs. Some officials are pursuing legal remedies. New Jersey sued Stamford, CT-based Purdue Pharma, pinning blame for the state’s opioid crisis on the drug maker’s marketing tactics to doctors and patients.
=================================================================